We Work For Health Statement Concerning The White House's ‘Great Healthcare Plan’ Announcement

We appreciate the administration's continued focus on making healthcare more affordable for American families. The rising cost is a genuine concern, and policymakers are right to demand accountability from those responsible. That's why we commend the administration's and Congress’ efforts to hold healthcare middlemen, including corporate insurers and their subsidiaries, accountable for their anti-competitive practices and opacity that drive up costs throughout the entire system. 

Codifying most favored nation (MFN) pricing into law, however, is the wrong approach. Research shows that price controls do nothing to lower out-of-pocket costs for patients. Instead, these policies would undermine America's biopharmaceutical innovation ecosystem at precisely the wrong moment. 

Since the start of 2025, the life sciences industry has announced commitments of more than $500 billion in new U.S. investments to drive research and development, expand manufacturing and create jobs nationwide. MFN pricing would threaten this investment just as it's accelerating, weakening our competitive position as China aggressively works to overtake American leadership in biomedical innovation. Importing the same failed foreign pricing policies that other countries use would deliver China the very advantage it seeks.

Real healthcare affordability requires real solutions, including recent efforts by lawmakers to enact PBM reform through bipartisan legislation. We look forward to next week’s Energy & Commerce and Ways & Means committee hearings featuring executives from the health insurance industry and hope this will be an opportunity to discuss reforms that hold insurers and PBMs accountable, increase transparency and put patients – not middlemen – at the center of our healthcare system.